Key facts
- Iaso Therapeutics’s last known valuation is $5.3M (Jan 2023).
- It has raised $1.8M across 2 recorded rounds; the latest was Seed Round ($570K) in Jan 2026.
- Notable investors include US National Science Foundation, Michigan Rise, Apjohn Group, Biosciences Research and Commercialization Center, National Institute Of Allergy and Infectious Diseases — 6 tracked in total.
- Iaso Therapeutics has filed 1 Form D with the SEC, most recently Jan 2023 ($438K sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Iaso Therapeutics
Funding rounds
2 roundsAbout Iaso Therapeutics
Operator of synthetic antigen-based vaccines designed to prevent and treat infectious diseases. The company offers a platform integrating precision-engineered antigens with a virus-like particle carrier providing strong immunogenicity, extensive conjugation capacity, and controlled synthetic design, enabling healthcare providers and research institutions to accelerate vaccine development, expand immune coverage, and improve durability against emerging pathogens.
- Sector
- Healthcare
- HQ
- East Lansing, MI, United States
- Founded
- 2018
- Employees
- 4
- Website
- iasotherapeutics.com/
- Ownership
- Privately Held (backing)
Iaso Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iaso Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iaso Therapeutics in its N-PORT filings yet. We sweep new filings monthly.